CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-03-03 | Labrucherie Gil M SVP & Chief Financial Officer | Exercise or conversion · Stock Option | −25,000 | 0 | ||
| 2017-03-02 | Labrucherie Gil M SVP & Chief Financial Officer | Exercise or conversion | +167,506 | $6.34 | $1.1M | 236,776 |
| 2017-03-02 | Labrucherie Gil M SVP & Chief Financial Officer | Sale | −167,506 | $15.15 | $2.5M | 69,270 |
| 2017-03-02 | Labrucherie Gil M SVP & Chief Financial Officer | Exercise or conversion · Stock Option | −167,506 | 7,494 | ||
| 2017-02-21 | Lingnau Lutz Director | Exercise or conversion | +30,000 | $5.14 | $154K | 60,450 |
| 2017-02-21 | Lingnau Lutz Director | Sale | −30,000 | $13.08 | $392K | 30,450 |
| 2017-02-21 | Lingnau Lutz Director | Exercise or conversion · Stock Option | −30,000 | 0 | ||
| 2017-02-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −1,965 | $13.14 | $26K | 55,637 |
| 2017-02-16 | ROBIN HOWARD W President & CEO | Sale | −8,636 | $13.14 | $113K | 169,272 |
| 2017-02-16 | Nicholson John SVP & Chief Operating Officer | Sale | −3,237 | $13.14 | $43K | 182,089 |
| 2017-02-16 | Labrucherie Gil M SVP & Chief Financial Officer | Sale | −2,359 | $13.14 | $31K | 69,270 |
| 2017-02-16 | Hora Maninder SVP Pharma Dev & Mfg Ops | Sale | −2,195 | $13.14 | $29K | 63,648 |
| 2017-02-16 | Gergel Ivan P. SVP & Chief Medical Officer | Sale | −1,457 | $13.14 | $19K | 45,022 |
| 2017-02-16 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −1,261 | $13.14 | $17K | 34,504 |
| 2017-02-10 | Nicholson John SVP & Chief Operating Officer | Exercise or conversion | +45,000 | $4.65 | $209K | 185,326 |
| 2017-02-10 | Nicholson John SVP & Chief Operating Officer | Exercise or conversion · Employee Stock Option (right to buy) | −45,000 | 0 | ||
| 2017-02-08 | ROBIN HOWARD W President & CEO | Exercise or conversion | +87,500 | $4.65 | $407K | 265,408 |
| 2017-02-08 | ROBIN HOWARD W President & CEO | Sale | −87,500 | $13.04 | $1.1M | 177,908 |
| 2017-02-08 | ROBIN HOWARD W President & CEO | Exercise or conversion · Stock Option | −87,500 | 0 | ||
| 2017-02-03 | Nicholson John SVP & Chief Operating Officer | Exercise or conversion | +8,505 | $4.65 | $40K | 148,831 |
Page 45 of 55 · 1,088 trades